&w=3840&q=100)
SIAC rules for Amazon in Future case, awards ₹23.7 crore damages
Amazon wins arbitration against Future Group at SIAC, but tribunal awards a fraction of claimed damages citing FRL's declining value and Covid-related business loss
New Delhi
The Singapore International Arbitration Centre (SIAC) has awarded ₹23.7 crore in damages, besides arbitration and litigation costs, to Amazon in its long-running dispute with the Kishore Biyani-led Future Group.
The three-member bench of the tribunal held that Future Group had breached the terms of its contract with Amazon by entering into a transaction with Reliance. It also told 11 promoters and parties of the Future Group, including Kishore Biyani, to pay the amount along with interest from March 9, 2022 till now.
The dispute pertains to a decision by the Future Group to sell its Big Bazaar retail business to Reliance Retail, a subsidiary of Reliance Industries.
Amazon had in 2022 argued before the Supreme Court of India that its ₹1,400-crore investment in the Future Group does not allow the latter to sell its assets to certain companies, which includes Reliance.
Amazon had, however, sought ₹1,436 crore damages, citing Future Retail Limited's (FRL) 'deteriorating value.'
SIAC ruled that Amazon was entitled to damages due to promoters' breaches of the Future Coupons Private Limited (FCPL) shareholders agreement, but rejected ₹1,436 crore damages sought by Amazon.
The tribunal reasoned that though all contractual obligations were fulfilled by Amazon, it would not have recovered its entire investment due to FRL'S deteriorating business value.
The tribunal said awarding Amazon damages in full would unfairly shield it from commercial loss it was bound to incur due to the Covid-19 pandemic and the deteriorating value of FRL.
Amazon was awarded ₹77.3 crore and Singapore dollars 68,550 as litigation cost.
In August 2020, Future Group, facing financial distress and debts of around ₹22,000 crore decided to sell its wholesale, logistics, and warehousing business to Reliance Industries for ₹24,713 crore. Amazon objected to this citing violation of their contractual obligations.
Amazon then started arbitration proceedings against Future Group in October 2020, obtaining an emergency arbitration award pausing the Future-Reliance deal.
Amazon and Future Group both took the matter to the Delhi High Court, Supreme Court of India, and the National Company Law Appellate Tribunal to resolve the issue.
The Competition Commission of India (CCI) had also imposed a fine of ₹200 crore on Amazon for non-disclosure of information on combinations under the Competition Act 2002.
Amazon had then moved the Supreme Court against the CCI ruling suspending approval for the ecommerce giant's 2019 deal investment in Future Group on January 10, 2023.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
41 minutes ago
- Time of India
Amazon to open up its fulfillment centers in India for public tours
Academy Empower your mind, elevate your skills Curious to know how your package travels from a simple click on the screen all the way to your doorstep?Now, you can experience a key part of that journey firsthand with Amazon fulfillment centers (its smart warehouses) in India opening doors for public Q4 2025, the ecommerce giant will offer a peek at behind-the-scenes logistics of packages through free in-person tours of its fulfillment centers (FC) in Delhi NCR and these 45 to 60-minutes guided tours, visitors can catch the action before the package reaches consumers' doorstep, in the process exploring facilities where millions of products are stored and customer orders processed and shipped daily, Amazon said on Monday as it announced the expansion of its public tour program to initiative invites interested visitors to visit Amazon's fulfillment centers, offering a glimpse into the technology and an opportunity to meet the people behind customer deliveries, the release made the announcement at the 'Delivering the Future' event in Tokyo, which showcases the company's latest innovations and tours will run three times weekly at both Delhi NCR and Bengaluru FCs, accommodating up to 20 participants per keen on these tours will be able to register online later this year and experience the behind-the-scenes operations."These tours offer visitors a behind-the-scenes look at the technology and people working together to deliver for our customers every day," Abhinav Singh, VP Operations India and Australia centre in Delhi NCR, the largest fulfillment center in North India, spans 4,50,000 square feet, a size equivalent to eight football Bengaluru facility is Amazon's largest fulfillment center in the country with over 2 million cubic feet of storage Boone-Lutz, who leads the public tours program at Amazon said, "Since 2014, we've welcomed over 2 million visitors across more than 35 locations in the US, Canada, the UK, Australia, France, Germany, and Italy."
Mint
41 minutes ago
- Mint
‘Trade talks with US resume', says Canadian PM Carney after rescinding digital services tax
Canadian Prime Minister Mark Carney said late Sunday that trade talks with the U.S. have resumed after Canada rescinded its plan to tax U.S. technology firms. U.S. President Donald Trump said on Friday that he was suspending trade talks with Canada over its plans to continue with its tax on technology firms, which he called 'a direct and blatant attack on our country.' The Canadian government said 'in anticipation' of a trade deal, Canada would rescind' the Digital Serves Tax. The tax was set to go into effect Monday, AP reported. Carney and Trump spoke on the phone Sunday, and Carney's office said they agreed to resume negotiations. 'Today's announcement will support a resumption of negotiations toward the July 21, 2025, timeline set out at this month's G7 Leaders' Summit in Kananaskis,' Carney said in a statement. In May, Carney visited Trump at the White House, where he maintained a courteous but firm stance. Later, during the G7 summit held in Alberta, Trump traveled to Canada, and both leaders agreed to set a 30-day deadline to resolve ongoing trade discussions. However, in a post on his social media platform last Friday, Trump stated that Canada had notified the U.S. it would proceed with implementing its digital services tax. The tax was aimed at both domestic and international companies interacting with Canadian online users. The 3% levy was set to impact major U.S. firms such as Amazon, Google, Meta, Uber, and Airbnb, applying to their revenues generated from Canadian users. Due to its retroactive nature, the tax would have resulted in an estimated $2 billion bill for these companies, payable by the end of the month. Canada and the U.S. have been discussing easing a series of steep tariffs Trump imposed on goods from America's neighbor. Trump has imposed 50% tariffs on steel and aluminum as well as 25% tariffs on autos. He is also charging a 10% tax on imports from most countries, though he could raise rates on July 9, after the 90-day negotiating period he set would expire. Canada and Mexico face separate tariffs of as much as 25% that Trump put into place under the auspices of stopping fentanyl smuggling, though some products are still protected under the 2020 U.S.-Mexico-Canada Agreement signed during Trump's first term. (With inputs from agencies)
Mint
an hour ago
- Mint
Alembic Pharma surges over 12% on USFDA approval for Cancer drug
Shares of Alembic Pharmaceuticals soared more than 12 percent in intra-day trade on Monday, June 30, after the company announced that it had secured final approval from the US Food and Drug Administration (USFDA) for its generic version of Doxorubicin Hydrochloride Liposome Injection. The drug is used in the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. The development marks yet another milestone in the company's growing US generics portfolio and sent investor sentiment soaring. Alembic Pharmaceuticals, in its official press release, said it received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection in two dosage forms—20 mg/10 mL and 50 mg/25 mL single-dose vials. The approved product is a therapeutic equivalent to Baxter Healthcare Corporation's Doxil Liposome Injection. The total market size for the drug in the US is estimated at USD 29 million for the twelve months ending March 2025, according to IQVIA. The approval strengthens Alembic's US generics pipeline, bringing its total number of ANDA approvals to 224, including 201 final and 23 tentative approvals. This comes close on the heels of another recent approval—earlier in June, Alembic had also received final USFDA clearance for its amlodipine and atorvastatin tablets, prescribed for hypertension management. The consistent momentum in product launches, especially in complex generics, underscores the company's focus on expanding its presence in the US market. This strategy has been a key earnings driver and is likely to support Alembic's revenue visibility in the coming quarters. In addition to regulatory milestones, Alembic Pharma also announced a dividend for the financial year ending March 31, 2025. The record date to determine eligible shareholders has been set for Tuesday, July 29, 2025. The dividend will be distributed post the Annual General Meeting scheduled for August 5 and will be paid on or after August 7. The company has a track record of consistent dividend payouts, having announced 14 dividends since July 2012. In the past year alone, it declared a total equity dividend of ₹ 11 per share. Alembic's financial performance also lent support to the stock's rally. The company reported a 14 percent year-on-year rise in consolidated net profit at ₹ 24 crore in Q4 FY25, compared to ₹ 21 crore in the same quarter last year. Operational revenue grew to ₹ 60 crore from ₹ 49 crore a year earlier. For the full FY25, net profit rose to ₹ 145 crore, a 56 percent increase from ₹ 93 crore reported in FY24. The pharma stock jumped as much as 12.13 percent to its day's high of ₹ 1089.80. It is now just 16 percent away from its 52-week high of ₹ 1,296.15, hit in October 2024. Meanwhile, it touched its 52-week low of ₹ 725.60 in March 2025. In the last 1 year, the stock has added over 10 percent. Moreover, it advanced 6 percent in June after an over 16 percent rise in May. In April, it fell 5.8 percent after a 25 percent rally in March. Before that, it was in the red in 5 straight months between October 2024-Feb 2025. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
